{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:29:56Z","timestamp":1772177396350,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,26]]},"DOI":"10.7759\/cureus.104339","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:22:01Z","timestamp":1772169721000},"source":"Crossref","is-referenced-by-count":0,"title":["Differentiating Autoimmune Hepatitis From Sulfasalazine Toxicity: The Value of Clinicopathologic Correlation"],"prefix":"10.7759","author":[{"given":"Adam","family":"Zoubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Bakhati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Sulfasalazine","author":"Hoofnagle JH","year":"2026","unstructured":"Hoofnagle JH. Sulfasalazine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2026."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-48","article-title":"Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events","volume":"9","author":"Jobanputra P","year":"2008","unstructured":"Jobanputra P, Amarasena R, Maggs F, et al.. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 2008, 9:48. 10.1186\/1471-2474-9-48","journal-title":"BMC Musculoskelet Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana RJ","year":"2023","unstructured":"Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023, 77:1036-65. 10.1002\/hep.32689","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade RJ","year":"2019","unstructured":"Andrade RJ, Aithal GP, Bj\u00f6rnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019, 70:1222-61. 10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0189","article-title":"Recent updates on the management of autoimmune hepatitis","volume":"27","author":"Komori A","year":"2021","unstructured":"Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol. 2021, 27:58-69. 10.3350\/cmh.2020.0189","journal-title":"Clin Mol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80221-6","article-title":"Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P","volume":"99","author":"Arnett FC","year":"1995","unstructured":"Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med. 1995, 99:465-72. 10.1016\/S0002-9343(99)80221-6","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7020-3410-7.00012-5","article-title":"Acute viral hepatitis","author":"Lefkowitch JH","year":"2010","unstructured":"Lefkowitch JH. Acute viral hepatitis. Scheuer's Liver Biopsy Interpretation, Eighth Edition. Saunders, Philadelphia, PA; 2010. 75-91. 10.1016\/B978-0-7020-3410-7.00012-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003980","article-title":"Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation","volume":"10","author":"Abhishek A","year":"2024","unstructured":"Abhishek A, Grainge M, Card T, et al.. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open. 2024, 10:e003980. 10.1136\/rmdopen-2023-003980","journal-title":"RMD Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/459481-differentiating-autoimmune-hepatitis-from-sulfasalazine-toxicity-the-value-of-clinicopathologic-correlation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:22:02Z","timestamp":1772169722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/459481-differentiating-autoimmune-hepatitis-from-sulfasalazine-toxicity-the-value-of-clinicopathologic-correlation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.104339","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}